3,723 Shares in Novo Nordisk A/S (NYSE:NVO) Acquired by Wealthgarden F.S. LLC

Wealthgarden F.S. LLC purchased a new position in Novo Nordisk A/S (NYSE:NVO) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 3,723 shares of the company’s stock, valued at approximately $531,000.

A number of other institutional investors have also recently made changes to their positions in the stock. 1620 Investment Advisors Inc. purchased a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at about $25,000. Gilliland Jeter Wealth Management LLC raised its stake in shares of Novo Nordisk A/S by 200.0% during the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after acquiring an additional 120 shares in the last quarter. First PREMIER Bank bought a new stake in shares of Novo Nordisk A/S in the 1st quarter worth approximately $25,000. Dixon Mitchell Investment Counsel Inc. purchased a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at $26,000. Finally, Orion Capital Management LLC purchased a new position in Novo Nordisk A/S in the 1st quarter worth $26,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 4.2 %

Shares of NYSE:NVO opened at $135.17 on Thursday. The firm has a market capitalization of $606.58 billion, a P/E ratio of 46.61, a P/E/G ratio of 1.43 and a beta of 0.42. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.75 and a current ratio of 0.94. The stock has a 50 day moving average price of $134.18 and a 200-day moving average price of $132.75. Novo Nordisk A/S has a 52-week low of $86.96 and a 52-week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing the consensus estimate of $0.71 by ($0.06). The firm had revenue of $9.82 billion for the quarter, compared to analysts’ expectations of $9.91 billion. Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.11 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were issued a dividend of $0.5126 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a dividend yield of 0.7%. Novo Nordisk A/S’s payout ratio is 24.83%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Argus upped their price target on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, June 10th. BMO Capital Markets reduced their price target on Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Monday. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 19th. Finally, The Goldman Sachs Group initiated coverage on shares of Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 target price on the stock. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S has an average rating of “Moderate Buy” and a consensus target price of $145.17.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.